[go: up one dir, main page]

CN104856968B - A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof - Google Patents

A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof Download PDF

Info

Publication number
CN104856968B
CN104856968B CN201510275397.XA CN201510275397A CN104856968B CN 104856968 B CN104856968 B CN 104856968B CN 201510275397 A CN201510275397 A CN 201510275397A CN 104856968 B CN104856968 B CN 104856968B
Authority
CN
China
Prior art keywords
add
chinese medicine
borneol
extract
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510275397.XA
Other languages
Chinese (zh)
Other versions
CN104856968A (en
Inventor
韩志强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hebei Baishan Pharmaceutical Co ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510275397.XA priority Critical patent/CN104856968B/en
Publication of CN104856968A publication Critical patent/CN104856968A/en
Application granted granted Critical
Publication of CN104856968B publication Critical patent/CN104856968B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

本发明提供了一种具有消栓通络作用的中药片剂,原料为黄芪400~450重量份,川芎250~300重量份,丹参200~250重量份,三七130~160重量份,泽泻130~160重量份,桂枝130~160重量份,郁金130~160重量份,山楂130~160重量份,槐花60~90重量份,木香60~90量份,冰片5~8重量份;本发明还提供了该中药片剂的制备方法,以该法更为简单、合理,所制得上述中药片剂中有效成分含量更高。The invention provides a traditional Chinese medicine tablet with the effect of eliminating blood clots and dredging collaterals. The raw materials are 400-450 parts by weight of Astragalus, 250-300 parts by weight of Rhizoma Chuanxiong, 200-250 parts by weight of Salvia Miltiorrhiza, 130-160 parts by weight of Panax notoginseng, Alisma 130-160 parts by weight, 130-160 parts by weight of cassia twig, 130-160 parts by weight of turmeric, 130-160 parts by weight of hawthorn, 60-90 parts by weight of Sophora japonica, 60-90 parts by weight of woody fragrance, 5-8 parts by weight of borneol part; the present invention also provides a preparation method of the Chinese medicine tablet, which is simpler and more reasonable, and the content of active ingredients in the above-mentioned Chinese medicine tablet is higher.

Description

一种具有消栓通络作用的中药片剂及其制备方法A traditional Chinese medicine tablet with the effect of eliminating blood clots and dredging collaterals and preparation method thereof

技术领域technical field

本发明涉及医药领域的药用制剂,具体是一种具有消栓通络作用的中药片剂及其制备方法。The invention relates to medicinal preparations in the field of medicine, in particular to a traditional Chinese medicine tablet with the effect of eliminating blood clots and dredging collaterals and a preparation method thereof.

背景技术Background technique

消栓通络片为中国药典收载品种。由川芎、丹参、黄芪、泽泻、三七、槐花、桂枝、郁金、木香、冰片、山楂制备而成,具有活血化瘀,温经通络的功能。临床上用于治疗血脂增高、中风(脑血栓)恢复期(一年内)半身不遂,肢体麻木、手足发凉、言语迟缓等症,是治疗心血管疾病的传统中药复方制剂。Xiaoshuan Tongluo Tablet is listed in the Chinese Pharmacopoeia. It is prepared from Rhizoma Chuanxiong, Salvia, Astragalus, Alisma, Panax notoginseng, Sophora japonica, Guizhi, Turmeric, Woody Fragrance, Borneol, and Hawthorn. It has the functions of promoting blood circulation, removing blood stasis, and warming meridians. It is clinically used to treat hyperlipidemia, stroke (cerebral thrombosis) recovery period (within one year) hemiplegia, numb limbs, cold hands and feet, slow speech, etc. It is a traditional Chinese medicine compound preparation for the treatment of cardiovascular diseases.

中风是导致人类死亡的三大疾病之一,是因病致残的首要原因,也是世界范围内一个主要的公共健康负担。对中风病理生理和防治药物的长期研究表明,这类疾病危险因素众多、病理生理变化繁复,单独应用某一化学或生物制剂难以收到良好的治疗效果。而以综合调理为特点的中药制剂——消栓通络片在该类疾病的治疗中效果良好。但现有消栓通络片的工艺基本是沿用传统汤剂的方法,三七、冰片以外的原料药水煎煮3次提取。该方法对有效成分提取率低,还不可避免的提出大量水溶性杂质。中药防病治病的效果与提取物的量及其中有效成分的含量有直接关系。倘若提取工艺不合理、不科学,势必造成有效成分的破坏和损失,从而影响制剂的质量、疗效。此外,现有消栓通络片的崩解时间较长,特别长期放置后,有超出药典标准的现象,崩解时间过长会严重影响药物的吸收。Stroke is one of the three major diseases leading to human death, the leading cause of disability due to disease, and a major public health burden worldwide. Long-term studies on the pathophysiology and prevention and treatment of stroke have shown that there are many risk factors and complex pathophysiological changes in such diseases, and it is difficult to obtain good therapeutic effects by using a single chemical or biological agent. However, Xiaoshuan Tongluo Tablet, a traditional Chinese medicine preparation characterized by comprehensive conditioning, has a good effect in the treatment of such diseases. But the technology of existing Xiaoshuan Tongluo Tablet is to continue to use the method of traditional decoction basically, and the raw material medicinal water other than Radix Notoginseng and Borneolum is decocted 3 times to extract. This method has a low extraction rate of active ingredients, and a large amount of water-soluble impurities is inevitably proposed. The effect of traditional Chinese medicine on disease prevention and treatment is directly related to the amount of extract and the content of active ingredients in it. If the extraction process is unreasonable and unscientific, it will inevitably cause damage and loss of active ingredients, thereby affecting the quality and curative effect of the preparation. In addition, the disintegration time of the existing Xiaoshuan Tongluo Tablet is relatively long, especially after long-term storage, it may exceed the pharmacopoeia standard. Too long disintegration time will seriously affect the absorption of the drug.

随着制临床上对药品质量、效果要求的不断提高及制药工艺的不断发展,该工艺已不能满足当前需求,急需一种有效成分提取更完全、含量更高的制剂,以更好地发挥消栓通络经典组方的药用价值。With the continuous improvement of drug quality and effect requirements in clinical practice and the continuous development of pharmaceutical technology, this technology can no longer meet the current needs. There is an urgent need for a preparation with more complete extraction of active ingredients and higher content to better play a role in the elimination of drugs. Medicinal value of classic formula of Shuan Tongluo.

发明内容Contents of the invention

本发明的目的是针对现有技术中存在的不足,提供一种有效成分提取更完全、含量更高的消栓通络片,从而更好地发挥该传统验方的药用价值。The purpose of the present invention is to address the deficiencies in the prior art and provide a Xiaoshuan Tongluo Tablet with more complete extraction of active ingredients and a higher content, so as to better exert the medicinal value of the traditional prescription.

本发明提供了一种具有消栓通络作用的中药片剂,该中药片剂的原料为:黄芪400~450重量份,川芎250~300重量份,丹参200~250重量份,三七130~160重量份,泽泻130~160重量份,桂枝130~160重量份,郁金130~160重量份,山楂130~160重量份,槐花60~90重量份,木香60~90量份,冰片5~8重量份;The invention provides a traditional Chinese medicine tablet with the effect of eliminating blood clots and dredging collaterals. The raw materials of the Chinese medicine tablet are: 400-450 parts by weight of Astragalus, 250-300 parts by weight of Rhizoma Chuanxiong, 200-250 parts by weight of Salvia Miltiorrhiza, 130-30 parts by weight of Panax notoginseng 160 parts by weight, 130-160 parts by weight of Alisma, 130-160 parts by weight of cassia twig, 130-160 parts by weight of turmeric, 130-160 parts by weight of hawthorn, 60-90 parts by weight of Sophora japonica, 60-90 parts by weight of woody fragrance , 5 to 8 parts by weight of borneol;

该中药片剂由以下制备方法制得:This Chinese medicine tablet is made by following preparation method:

⑴取上述三七、冰片之外的原料,加3~5倍量的温水(蒸馏水)及3~5%(以药材重量计)的复合酶,混匀,45~55℃保温酶解1~2小时;补加水后以水蒸汽蒸馏法提取2次,收集挥发油,滤液合并浓缩后加乙醇静置过夜,过滤,滤液回收乙醇,浓缩,得浸膏,浸膏密度1.1~1.15(50℃);所述的复合酶为纤维素酶与果胶酶的混合物;(1) Take the raw materials other than the above-mentioned notoginseng and borneol, add 3 to 5 times the amount of warm water (distilled water) and 3 to 5% (based on the weight of medicinal materials) of compound enzymes, mix well, keep warm at 45 to 55 ° C for 1 to 2 hours; after adding water, extract twice by steam distillation, collect volatile oil, combine and concentrate the filtrate, add ethanol and let it stand overnight, filter, recover ethanol from the filtrate, concentrate to obtain extract, the extract density is 1.1-1.15 (50°C) ; The compound enzyme is a mixture of cellulase and pectinase;

⑵将三七、冰片分别粉碎;(2) Crush notoginseng and borneol separately;

⑶将步骤⑵得到的浸膏与三七粉混合,制粒,干燥;(3) Mix the extract obtained in step (2) with Panax notoginseng powder, granulate, and dry;

⑷向步骤⑶所得颗粒喷洒挥发油,加入冰片粉及硬脂酸镁,混合,压片、包薄膜衣,即得。(4) Spray volatile oil on the granules obtained in step (3), add borneol powder and magnesium stearate, mix, compress into tablets, and coat with film to obtain final product.

上述硬脂酸镁的用量为1%(w/w),即,硬脂酸镁占总片重的1%。The consumption of above-mentioned magnesium stearate is 1% (w/w), namely, magnesium stearate accounts for 1% of total tablet weight.

原料药中的川芎、郁金、桂枝和木香都含有大量挥发性有效成分,现有工艺直接水提取的方法势必造成该部分成分的浪费。Ligusticum chuanxiong, turmeric, cassia twig and woody incense in the raw materials all contain a large amount of volatile active ingredients, and the method of direct water extraction in the existing technology will inevitably cause waste of these ingredients.

近年来不断有人研究酶在中药提取中的应用,并取得了不错的效果。本发明采纳该先进技术,根据各原料药有效成分的性质特点对传统煎煮工艺进行了优化和改进。对于酶种类及用量的选择做了大量实验研究。最终得到上述制备方法及该法制得的片剂。该方法对提取物进行了纯化,在减少了大量杂质的情况下,得到的提取物(干浸膏)收率与现有方法相当,更重要的是,其中的黄芪甲苷及芦丁的含量均有不同程度所提高,即,提高了制剂中有效成分的含量,进而提高其疗效。In recent years, people have continuously studied the application of enzymes in the extraction of traditional Chinese medicine, and achieved good results. The present invention adopts the advanced technology, and optimizes and improves the traditional decoction process according to the properties and characteristics of the active ingredients of each crude drug. A large number of experimental studies have been done on the selection of enzyme types and dosage. Finally, the above-mentioned preparation method and the tablet prepared by the method are obtained. The method has purified the extract, and in the case of reducing a large amount of impurities, the yield of the obtained extract (dry extract) is equivalent to that of the existing method, and more importantly, the content of astragaloside IV and rutin therein All have different degrees of improvement, that is, the content of the active ingredient in the preparation is increased, thereby improving its curative effect.

为减少服用的无效成分量,本发明引入醇沉的步骤,以除去淀粉等水溶性杂质。发明人对于醇沉步骤中提取液浓缩的密度及醇浓度进行考察,从而兼顾到醇沉过程中耗醇量、回收乙醇的时间、有效成分的损耗等因素,最终,确定提取液浓缩至密度为1:(1~2)ml/g(即,每1~2g原药材浓缩至1ml),加乙醇至醇浓为50~60%(v/v)。In order to reduce the amount of ineffective ingredients taken, the present invention introduces the step of alcohol precipitation to remove water-soluble impurities such as starch. The inventor investigates the concentrated density and alcohol concentration of the extract in the alcohol precipitation step, so as to take into account factors such as the amount of alcohol consumed in the alcohol precipitation process, the time for recovering ethanol, the loss of active ingredients, and finally determine that the extract is concentrated to a density of 1: (1~2)ml/g (that is, every 1~2g of raw medicinal material is concentrated to 1ml), add ethanol until the alcohol concentration is 50~60% (v/v).

目前的提取工艺为水煎煮三次,仅该一环节所耗时间就在7~9小时(含中间环节时间),耗水22~24倍量。因该药为长期用药,且用药人群庞大,所以长期生产所耗电量及水量是惊人。本发明经过优化的制法不但提高了提取的效率,还节约了大量能源,同时也是对日趋紧缺的中药材的充分利用。The current extraction process is decocting three times in water, and the time spent in this step alone is 7 to 9 hours (including the time in the middle step), and the water consumption is 22 to 24 times the amount. Because the drug is used for a long time, and the number of people who use it is huge, the amount of electricity and water consumed for long-term production is astonishing. The optimized preparation method of the invention not only improves the extraction efficiency, but also saves a large amount of energy, and at the same time fully utilizes the increasingly scarce Chinese medicinal materials.

制备500片本发明中药片剂的原料为:黄芪428-435g,川芎285-290g,丹参210-220g,三七140-150g,泽泻140-150g,桂枝140-150g,郁金140-150g,山楂140-150g,槐花70-75g,木香70-75g,冰片5.5-6.0g;所述方法制得的该中药片剂的单位重量为0.76g/片。The raw materials for preparing 500 Chinese medicine tablets of the present invention are: Astragalus 428-435g, Rhizoma Chuanxiong 285-290g, Salvia miltiorrhiza 210-220g, Panax notoginseng 140-150g, Alisma 140-150g, Guizhi 140-150g, Curcuma 140-150g , hawthorn 140-150g, pagoda japonica 70-75g, woody fragrance 70-75g, borneol 5.5-6.0g; the unit weight of the traditional Chinese medicine tablet prepared by the method is 0.76g/piece.

制备500片该中药片剂的原料优选为:黄芪431g,川芎287g,丹参215g,三七144g,泽泻144g,桂枝144g,郁金144g,山楂144g,槐花72g,木香72g,冰片5.7g;该中药片剂的单位剂量为0.76g/片,即,该中药片剂(通用名为“消栓通络片”)的规格为0.76g/片。The raw materials for preparing 500 tablets of this traditional Chinese medicine are preferably: Astragalus 431g, Chuanxiong 287g, Salvia miltiorrhiza 215g, Panax notoginseng 144g, Alisma 144g, Guizhi 144g, Curcuma 144g, Hawthorn 144g, Sophora japonica 72g, Woody 72g, Borneol 5.7g g; the unit dose of the Chinese medicine tablet is 0.76g/piece, that is, the specification of the Chinese medicine tablet (commonly known as "Xiaoshuan Tongluo Tablet") is 0.76g/piece.

上述的复合酶为3:1的纤维素酶与果胶酶。植物组织中含有天然的纤维素酶抑制剂;它能保护植物免遭霉菌的腐烂作用,因此,不同的植物药材或组合,所适用的酶及用量是不尽相同的。酶的用量偏低时酶解的效果差,随着酶的浓度升高,与底物的接触面积增大,酶解反应速率增大,但并非越高越好,当酶达到某一浓度时则会产生抑制作用,酶得不到充分利用,造成浪费。因此,发明人对酶的种类及用量进行了考察,发现效果差异明显。其中以纤维素酶、果胶酶3:1比例组合的复合酶效果最佳,显著提高了黄芪甲苷的转移率,高达95.5%,较水提取法提升19%。The compound enzyme mentioned above is a 3:1 ratio of cellulase and pectinase. Plant tissue contains natural cellulase inhibitors; it protects plants from mold decay, so different botanicals or combinations require different enzymes and dosages. When the amount of enzyme is low, the effect of enzymatic hydrolysis is poor. As the concentration of enzyme increases, the contact area with the substrate increases, and the rate of enzymatic hydrolysis reaction increases, but the higher the better, when the enzyme reaches a certain concentration Inhibition will occur, and the enzyme will not be fully utilized, resulting in waste. Therefore, the inventors investigated the types and dosages of enzymes, and found that the effects were significantly different. Among them, the compound enzyme combined with cellulase and pectinase in a ratio of 3:1 has the best effect, which significantly improves the transfer rate of astragaloside IV, which is as high as 95.5%, which is 19% higher than that of the water extraction method.

此外,酶解温度及酶解时间也对酶解效果有较大影响。筛选实验结果表明,最佳酶解条件为:50℃、1小时。In addition, the enzymatic hydrolysis temperature and enzymatic hydrolysis time also have a great influence on the enzymatic hydrolysis effect. The screening experiment results showed that the best enzymatic hydrolysis conditions were: 50°C, 1 hour.

在酶的作用下,不但提高了提取效果,还明显减少了水提取的时间及次数。该所述步骤⑴的提取方法具体为:首次8~10倍量水提取1小时,第二次6~8倍量水0.5小时。Under the action of enzymes, not only the extraction effect is improved, but also the time and times of water extraction are significantly reduced. The extraction method of said step (1) is specifically: the first 8-10 times the amount of water extraction for 1 hour, the second 6-8 times the amount of water for 0.5 hours.

所述步骤⑴进一步为:提取滤液浓缩至1:(1~2)ml/g,搅拌下缓慢加入乙醇至醇浓度为50%(v/v),静置12~18小时。The step (1) is further as follows: the extraction filtrate is concentrated to 1: (1-2) ml/g, slowly adding ethanol under stirring until the alcohol concentration is 50% (v/v), and standing for 12-18 hours.

所述的步骤⑶为将三七粉与崩解剂混匀,加到步骤⑵所得的浸膏中制软材,制粒,干燥。其中,所述的崩解剂为交联聚维酮和/或交联羧甲基纤维素钠。在一优选实施例中,所述的崩解剂为用量比为2:1的交联聚维酮与交联羧甲基纤维素钠,用量为2~5%(w/w),优选2%。The step (3) is to mix the Panax notoginseng powder and the disintegrating agent, add it to the extract obtained in the step (2) to make a soft material, granulate, and dry. Wherein, the disintegrant is crospovidone and/or croscarmellose sodium. In a preferred embodiment, the disintegrating agent is crospovidone and croscarmellose sodium at a dosage ratio of 2:1, and the dosage is 2 to 5% (w/w), preferably 2 %.

以中药提取物为主要组成部分的片剂,由于提取物成分多且复杂自身粘度较高,一般崩解时间都偏长,特别是长期放置后,崩解时间继续延长的趋势明显。因此,本发明添加了适量崩解剂,添加崩解剂后所制成的片剂崩解时间在15分钟左右,加速放置6个月后也在22分钟左右完全崩解。有效避免了崩解过缓对疗效造成的不利影响。Tablets with traditional Chinese medicine extracts as the main component generally take a long time to disintegrate due to the complexity and high viscosity of the extract. Especially after long-term storage, the disintegration time tends to continue to prolong obviously. Therefore, the present invention adds an appropriate amount of disintegrant, and the disintegration time of the tablet made after adding the disintegrant is about 15 minutes, and it also disintegrates completely in about 22 minutes after accelerated placement for 6 months. Effectively avoid the adverse effect of slow disintegration on the curative effect.

本发明所述中药片剂的制备方法将提取物浸膏直接与三七粉等混合制粒,减少了该部分提取物干燥粉碎的步骤,简化了工艺步骤,提高了生产效率。In the preparation method of the traditional Chinese medicine tablet of the invention, the extract extract is directly mixed with notoginseng powder and the like to granulate, which reduces the steps of drying and pulverizing the part of the extract, simplifies the process steps, and improves the production efficiency.

发明人通过以下试验考察不同工艺步骤及参数对本发明中药片剂的影响。The inventor investigates the influence of different processing steps and parameters on the Chinese medicine tablet of the present invention by following tests.

再次重申:以下试验只是本发明研制过程中众多试验中的举例性试验,并未涵盖和穷尽了发明人为本发明所做的所有实验,目的仅仅在于用那些数据来阐述本发明中药片剂制备方法筛选优化的部分过程及结果。Reiterate again: following test is just the exemplary test in numerous tests in the development process of the present invention, does not cover and exhaust all experiments that the inventor has done for the present invention, purpose is only to set forth Chinese medicine tablet preparation method of the present invention with those data Part of the process and results of screening optimization.

一、酶种类及用量的筛选实验1. Screening experiment of enzyme type and dosage

1、供试样品:按照上述中药片剂的优选原料配比称取黄芪、川芎、丹参、泽泻、桂枝、郁金、山楂、槐花和木香,粉碎成粗颗粒,混合,称取混合原料药50g/份,共30份。1. Samples for testing: weigh Astragalus, Chuanxiong, Salvia, Alisma, Cinnamon Twig, Curcuma, Hawthorn, Sophora japonica and Muxiang according to the optimal raw material ratio of the above-mentioned Chinese medicine tablet, grind them into coarse particles, mix, weigh Mix raw material medicine 50g/ part, totally 30 parts.

2、实验方法:以直接水煎煮提取法为对照,比较几种酶及不同用量对本发明原料药提取有效成分的影响。2. Experimental method: taking the direct water decoction extraction method as a contrast, compare the influence of several enzymes and different dosages on the extraction of active ingredients from the crude drug of the present invention.

其中,水煎煮法为:水煎煮1次,10倍量水煎煮2小时,滤液,测定并计算黄芪甲苷转移率。Among them, the water decoction method is: water decoction once, 10 times the amount of water decoction for 2 hours, and the filtrate is used to measure and calculate the transfer rate of astragaloside IV.

酶解法:向混合原料药中加4倍量温水,按照表1中酶种类及用量加入水中,混匀,45℃保温1.5小时,补水至8倍量,以水蒸汽蒸馏法提取1小时,滤液,测定并计算黄芪甲苷转移率。Enzymolysis method: add 4 times the amount of warm water to the mixed raw medicine, add the enzyme type and dosage in the water according to Table 1, mix well, keep warm at 45°C for 1.5 hours, add water to 8 times the amount, extract by steam distillation for 1 hour, and the filtrate , Determination and calculation of astragaloside IV transfer rate.

按照2010年版《中国药典》黄芪药材含量测定色谱条件测定黄芪甲苷。Astragaloside IV was determined according to the chromatographic conditions for the content determination of Astragalus membranaceus in the 2010 edition of "Chinese Pharmacopoeia".

样品处理:Sample handling:

提取液过滤后,分别精密量取2ml,置50ml容瓶中,加甲醇至刻度,以微孔滤膜(0.45μm)滤过,即得。配置黄芪甲苷对照品溶液约60ug/ml。After the extract is filtered, accurately measure 2ml respectively, put it in a 50ml volumetric flask, add methanol to the mark, and filter through a microporous membrane (0.45μm) to obtain the product. Configure astragaloside IV reference solution about 60ug/ml.

3、实验结果:实验数据表明,酶解后再进行提取,黄芪甲苷的转移率明显提升,且不同酶种间差异明显,其中以纤维素酶与果胶酶按3:1比例配合的复合酶效果最为显著,黄芪甲苷的转移率提高了19%;不同酶种的用量对黄芪甲苷转移率影响的趋势不同,如,中性蛋白酶不同用量间几乎没有影响,而纤维素酶用量4%酶解效率最高。详见表1。3. Experimental results: The experimental data show that after enzymatic hydrolysis and then extraction, the transfer rate of astragaloside IV is significantly improved, and the difference between different enzyme species is obvious. Among them, the compound of cellulase and pectinase in a ratio of 3:1 The effect of the enzyme is the most significant, and the transfer rate of astragaloside IV has increased by 19%. % Enzymolysis efficiency is the highest. See Table 1 for details.

表1 酶种类及用量的筛选试验结果Table 1 Screening test results of enzyme types and dosage

二、酶解温度的考察Second, the investigation of enzymatic hydrolysis temperature

1、供试样品:同实验一。1. Test sample: Same as Experiment 1.

2、实验方法:在实验一酶解法的基础上,以3:1的纤维素酶与果胶酶为复合酶,分别按照表2考察不同酶解温度对黄芪甲苷转移率的影响。2. Experimental method: Based on the enzymatic hydrolysis method of Experiment 1, using 3:1 cellulase and pectinase as the compound enzyme, the effects of different enzymatic hydrolysis temperatures on the transfer rate of astragaloside IV were investigated according to Table 2.

3、实验结果:实验数据表明,酶解温度自35℃至50℃间,随温度升高黄芪甲苷的转移率不断提高,到60℃时下降趋势明显,因此,在45℃至55℃间均有良好的酶解效果,其中以50℃最佳。详见表2。3. Experimental results: The experimental data shows that the transfer rate of astragaloside IV increases continuously with the increase of temperature from 35°C to 50°C, and the downward trend is obvious when the temperature reaches 60°C. All have good enzymatic hydrolysis effects, among which 50°C is the best. See Table 2 for details.

表2 酶解温度的考察结果Table 2 The investigation results of enzymatic hydrolysis temperature

组号Group No 酶解温度Enzyme temperature 黄芪甲苷转移率%Transfer rate of astragaloside IV% 11 35℃35°C 85.585.5 22 40℃40℃ 91.491.4 33 45℃45°C 94.794.7 44 50℃50℃ 96.296.2 55 55℃55°C 95.195.1 66 60℃60℃ 92.992.9

三、酶解时间的考察3. Investigation of enzymatic hydrolysis time

1、供试样品:同实验一。1. Test sample: Same as Experiment 1.

2、实验方法:在实验一酶解法的基础上,以3:1的纤维素酶与果胶酶为复合酶,50℃为酶解温度条件下,考察酶解时间对对提取的影响。2. Experimental method: Based on the enzymatic hydrolysis method of Experiment 1, using 3:1 cellulase and pectinase as the compound enzyme and 50°C as the enzymatic hydrolysis temperature, the effect of enzymatic hydrolysis time on the extraction was investigated.

3、实验结果:实验数据表明,在同等条件下,酶解1~2小时间黄芪甲苷的转移率无显著差异,为提高生产效率,节约时间,优选酶解1小时。详见表3。3. Experimental results: Experimental data show that under the same conditions, there is no significant difference in the transfer rate of astragaloside IV within 1 to 2 hours of enzymatic hydrolysis. In order to improve production efficiency and save time, 1 hour of enzymatic hydrolysis is preferred. See Table 3 for details.

表3 酶解温度的考察结果Table 3 Investigation results of enzymatic hydrolysis temperature

组号Group No 酶解时间Enzymolysis time 黄芪甲苷转移率%Transfer rate of astragaloside IV% 11 0.5小时0.5 hours 91.691.6 22 1小时1 hour 96.196.1 33 1.5小时1.5 hours 96.596.5 44 2小时2 hours 96.296.2

四、片剂中崩解剂的选择4. Selection of disintegrants in tablets

将本发明步骤⑴得到的浸膏与三七粉混合,加不同崩解剂2%(w/w)制粒,干燥;向颗粒喷挥发油,与冰片混匀,加硬脂酸镁混合后压片,包薄膜衣,按照药典方法检测崩解时限。结果表明,交联聚维酮和交联羧甲基纤维素钠均可明显加快崩解速度,特别是二者以2:1比例配合后,崩解时间显著缩短。详见表4。Mix the extract obtained in step (1) of the present invention with Panax notoginseng powder, add 2% (w/w) of different disintegrants to granulate, and dry; spray volatile oil to the granules, mix with borneol, add magnesium stearate, mix and press Tablets, film-coated, and tested for disintegration time according to the Pharmacopoeia method. The results show that both crospovidone and croscarmellose sodium can significantly accelerate the disintegration speed, especially when the two are combined at a ratio of 2:1, the disintegration time is significantly shortened. See Table 4 for details.

表4 崩解剂的选择结果Table 4 Selection results of disintegrants

组号Group No 崩解剂disintegrant 崩解时间(min)Disintegration time (min) 11 ———— 23.523.5 22 羧甲基淀粉钠Sodium carboxymethyl starch 22.622.6 33 交联羧甲基纤维素钠Croscarmellose Sodium 19.119.1 44 低取代羟丙基纤维素Low-substituted hydroxypropyl cellulose 20.520.5 55 交联聚维酮Crospovidone 17.817.8 66 交联聚维酮+交联羧甲基纤维素钠(1:1)Crospovidone + Croscarmellose Sodium (1:1) 17.217.2 77 交联聚维酮+交联羧甲基纤维素钠(2:1)Crospovidone + Croscarmellose Sodium (2:1) 15.315.3 88 交联聚维酮+交联羧甲基纤维素钠(1:2)Crospovidone + Croscarmellose Sodium (1:2) 19.419.4

具体实施方案specific implementation plan

实施例1Example 1

500片处方:500 tablet prescription:

黄芪431g,川芎287g,丹参215g,三七144g,泽泻144g,桂枝144g,郁金144g,山楂144g,槐花72g,木香72g,冰片5.7g;交联聚维酮5g,交联羧甲基纤维素钠2.5g,硬脂酸镁3.8g。Astragalus 431g, Chuanxiong 287g, Salvia 215g, Panax notoginseng 144g, Alisma 144g, Guizhi 144g, Curcuma 144g, Hawthorn 144g, Sophora japonica 72g, Woody 72g, Borneol 5.7g; Crospovidone 5g, Croscarboxyl Sodium methylcellulose 2.5g, magnesium stearate 3.8g.

制备方法:Preparation:

⑴取三七、冰片之外的上述原料,加3倍量的温水及4%的复合酶(3:1的纤维素酶与果胶酶,下同),混匀,50℃保温酶解1小时;补加蒸馏水至8倍量,水蒸汽蒸馏法提取2次,收集挥发油,第一次1小时,第二次加6倍量水0.5小时,合并煎液,过滤,滤液减压浓缩至1:1.5ml/g后加乙醇至醇浓度50%,静置12小时,过滤,滤液回收乙醇,浓缩,得浸膏,浸膏密度1.13(50℃);(1) Take the above-mentioned raw materials except Sanqi and Borneol, add 3 times the amount of warm water and 4% compound enzyme (3:1 cellulase and pectinase, the same below), mix well, keep warm at 50°C for enzymatic hydrolysis for 1 Add distilled water to 8 times the amount, extract 2 times by steam distillation, collect volatile oil, the first time for 1 hour, add 6 times the amount of water for 0.5 hours for the second time, combine the decoction, filter, and concentrate the filtrate under reduced pressure to 1 : After 1.5ml/g, add ethanol to alcohol concentration 50%, leave standstill for 12 hours, filter, the filtrate reclaims ethanol, concentrates to obtain extract, extract density 1.13 (50 ℃);

⑵将三七、冰片分别粉碎至100目,备用;⑵ Crush notoginseng and borneol to 100 mesh respectively, and set aside;

⑶将交联聚维酮、交联羧甲基纤维素钠与三七粉混匀,加到步骤⑵所得的浸膏中制软材,制粒,干燥;(3) mix crospovidone, croscarmellose sodium and notoginseng powder, add to the extract obtained in step (2) to make a soft material, granulate, and dry;

⑷向步骤⑶所得颗粒中喷洒挥发油,加入冰片粉及硬脂酸镁,混匀,压片、包薄膜衣,即得。上述方法制得的该中药片剂的单位重量为0.76g/片(即规格为0.76g/片)。(4) Spray volatile oil into the granules obtained in step (3), add borneol powder and magnesium stearate, mix well, press into tablets, and coat with film to obtain final product. The unit weight of the traditional Chinese medicine tablet prepared by the above method is 0.76g/tablet (that is, the specification is 0.76g/tablet).

实施例2Example 2

500片处方:500 tablet prescription:

黄芪431g,川芎287g,丹参215g,三七144g,泽泻144g,桂枝144g,郁金144g,山楂144g,槐花72g,木香72g,冰片5.7g;交联聚维酮3.8g,交联羧甲基纤维素钠3.8g,硬脂酸镁3.8g。Astragalus 431g, Chuanxiong 287g, Salvia miltiorrhiza 215g, Panax notoginseng 144g, Alisma 144g, Guizhi 144g, Curcuma 144g, Hawthorn 144g, Sophora japonica 72g, Woody fragrance 72g, Borneol 5.7g; Cross-linked povidone 3.8g, cross-linked Carboxymethylcellulose sodium 3.8g, magnesium stearate 3.8g.

制备方法与实施例1不同之处在于:The difference between the preparation method and Example 1 is:

⑴取三七、冰片之外的上述原料,加5倍量的温水及3%的复合酶,混匀,45℃保温酶解1.5小时;补加蒸馏水至10倍量,水蒸汽蒸馏法提取2次,收集挥发油,第二次加6倍量水,合并煎液,过滤,滤液浓缩至1:1ml/g后加乙醇至醇浓度60%,静置14小时,过滤,滤液回收乙醇,浓缩,得浸膏,浸膏密度1.1(50℃)。⑴ Take the above raw materials except Sanqi and Borneol, add 5 times the amount of warm water and 3% compound enzyme, mix well, keep warm at 45°C for 1.5 hours; add distilled water to 10 times the amount, and extract 2 The first time, collect the volatile oil, add 6 times the amount of water for the second time, combine the decoction, filter, add ethanol to the alcohol concentration of 60% after the filtrate is concentrated to 1:1ml/g, let it stand for 14 hours, filter, recover the ethanol from the filtrate, concentrate, Obtained extract, extract density 1.1 (50 ℃).

实施例3Example 3

500片处方:500 tablet prescription:

黄芪431g,川芎287g,丹参215g,三七144g,泽泻144g,桂枝144g,郁金144g,山楂144g,槐花72g,木香72g,冰片5.7g;交联聚维酮7.6g,硬脂酸镁3.8g。Astragalus 431g, Chuanxiong 287g, Salvia 215g, Panax notoginseng 144g, Alisma 144g, Guizhi 144g, Curcuma 144g, Hawthorn 144g, Sophora japonica 72g, Woody 72g, Borneol 5.7g; Crospovidone 7.6g, stearin Magnesium acid 3.8g.

制备方法与实施例1不同之处在于:The difference between the preparation method and Example 1 is:

⑴取三七、冰片之外的上述原料,加4倍量的温水及5%的复合酶,混匀,55℃保温酶解2小时;补加蒸馏水至8倍量,水蒸汽蒸馏法提取2次,收集挥发油,第二次加8倍量水,合并煎液,过滤,滤液浓缩至1:2ml/g后加乙醇至醇浓度55%,静置18小时,过滤,滤液回收乙醇,浓缩,得浸膏,浸膏密度1.15(50℃)。(1) Take the above-mentioned raw materials except Sanqi and Borneol, add 4 times the amount of warm water and 5% compound enzyme, mix well, keep warm at 55°C for 2 hours; add distilled water to 8 times the amount, and extract 2 The first time, collect the volatile oil, add 8 times the amount of water for the second time, combine the decoction, filter, add ethanol to the alcohol concentration of 55% after the filtrate is concentrated to 1:2ml/g, let it stand for 18 hours, filter, recover the ethanol from the filtrate, concentrate, Obtained extract, extract density 1.15 (50 ℃).

实施例4Example 4

500片处方:500 tablet prescription:

黄芪400g,川芎300g,丹参200g,三七160g,泽泻160g,桂枝130g,郁金160g,山楂130g,槐花60g,木香90g,冰片5g;硬脂酸镁3.8g。Astragalus 400g, Chuanxiong 300g, Salvia miltiorrhiza 200g, Panax notoginseng 160g, Alisma 160g, Guizhi 130g, Curcuma 160g, Hawthorn 130g, Sophora japonica 60g, Muxiang 90g, Borneol 5g; Magnesium stearate 3.8g.

制备方法同实施例1~3中任一方法。The preparation method is the same as any method in Examples 1-3.

实施例5Example 5

500片处方:500 tablet prescription:

黄芪450g,川芎250g,丹参250g,三七130g,泽泻130g,桂枝160g,郁金130g,山楂160g,槐花90g,木香60g,冰片8g;交联羧甲基纤维素钠7.6g,硬脂酸镁3.8g。Astragalus 450g, Chuanxiong 250g, Salvia miltiorrhiza 250g, Panax notoginseng 130g, Alisma 130g, Guizhi 160g, Curcuma 130g, Hawthorn 160g, Sophora japonica 90g, Woody fragrance 60g, Borneol 8g; Croscarmellose sodium 7.6g, Magnesium stearate 3.8g.

制备方法同实施例1~3中任一方法。The preparation method is the same as any method in Examples 1-3.

实施例6Example 6

500片处方为:The 500-tablet prescription is:

黄芪428g,川芎285g,丹参210g,三七140g,泽泻140g,桂枝140g,郁金140g,山楂140g,槐花70g,木香70g,冰片5.5g;崩解剂适量,其为用量比为2:1的交联聚维酮与交联羧甲基纤维素钠的组合。Astragalus 428g, Chuanxiong 285g, Salvia 210g, Sanqi 140g, Alisma 140g, Guizhi 140g, Curcuma 140g, Hawthorn 140g, Sophora japonica 70g, Woody Fragrance 70g, Borneol 5.5g; appropriate amount of disintegrating agent, the dosage ratio is 2:1 combination of crospovidone and croscarmellose sodium.

制备方法同实施例1~3中任一方法。The preparation method is the same as any method in Examples 1-3.

实施例7Example 7

500片处方为:The 500-tablet prescription is:

黄芪429g,川芎288g,丹参217g,三七147g,泽泻147g,桂枝137g,郁金149g,山楂145g,槐花72g,木香72g,冰片5.7g;崩解剂适量,其为用量比为2:1的交联聚维酮与交联羧甲基纤维素钠的组合。Astragalus 429g, Chuanxiong 288g, Salvia miltiorrhiza 217g, Panax notoginseng 147g, Alisma 147g, Guizhi 137g, Curcuma 149g, Hawthorn 145g, Sophora japonica 72g, Woody fragrance 72g, Borneol 5.7g; appropriate amount of disintegrating agent, the dosage ratio is 2:1 combination of crospovidone and croscarmellose sodium.

制备方法同实施例1~3中任一方法。The preparation method is the same as any method in Examples 1-3.

以上旨在进一步说明本发明,并不对本发明的范围加以限制。本领域技术人员对在此公开的实施方案可进行并不偏离本发明范畴和精神的改进和变化。The above is intended to further illustrate the present invention, but not to limit the scope of the present invention. Modifications and changes to the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.

Claims (3)

1.一种具有消栓通络作用的中药片剂,其特征在于,制备500片该中药片剂的原料为:黄芪431g,川芎287g,丹参215g,三七144g,泽泻144g,桂枝144g,郁金144g,山楂144g,槐花72g,木香72g,冰片5.7g;该中药片剂的单位重量为0.76g/片;1. A Chinese medicine tablet with the effect of eliminating blood clots and dredging collaterals, characterized in that the raw materials for preparing 500 pieces of this Chinese medicine tablet are: Radix Astragali 431g, Rhizoma Chuanxiong 287g, Salvia miltiorrhiza 215g, Panax notoginseng 144g, Alisma 144g, cassia twig 144g , turmeric 144g, hawthorn 144g, Sophora japonica 72g, woody fragrance 72g, borneol 5.7g; the unit weight of the traditional Chinese medicine tablet is 0.76g/piece; 该中药片剂由以下制备方法制得:This Chinese medicine tablet is made by following preparation method: ⑴取上述三七、冰片之外的原料,加3~5倍量的温水及3~5%的复合酶,混匀,45~55℃保温酶解1~2小时;补加水后以水蒸汽蒸馏法提取2次,首次8~10倍量水提取1小时,第二次6~8倍量水0.5小时;收集挥发油,滤液合并浓缩后加乙醇静置过夜,过滤,滤液回收乙醇,浓缩,得浸膏,浸膏密度在50℃时为1.1~1.15;所述的复合酶为3:1的纤维素酶与果胶酶;酶解温度为50℃,酶解时间为1小时;(1) Take the raw materials other than the above-mentioned notoginseng and borneol, add 3 to 5 times the amount of warm water and 3 to 5% compound enzyme, mix well, keep warm at 45 to 55°C for 1 to 2 hours; Distillation extraction twice, the first 8 to 10 times the amount of water extraction for 1 hour, the second 6 to 8 times the amount of water for 0.5 hours; collect volatile oil, combine and concentrate the filtrate, add ethanol and let stand overnight, filter, recover ethanol from the filtrate, concentrate, To obtain the extract, the density of the extract is 1.1 to 1.15 at 50°C; the compound enzyme is 3:1 cellulase and pectinase; the enzymolysis temperature is 50°C, and the enzymolysis time is 1 hour; ⑵将三七、冰片分别粉碎;(2) Crush notoginseng and borneol separately; ⑶将步骤⑵得到的浸膏与三七粉混合,制粒,干燥;(3) Mix the extract obtained in step (2) with Panax notoginseng powder, granulate, and dry; ⑷向步骤⑶所得颗粒喷洒挥发油,加入冰片粉及硬脂酸镁,混合,压片、包薄膜衣,即得;(4) spray volatile oil to the granules obtained in step (3), add borneol powder and magnesium stearate, mix, compress into tablets, coat with film, to obtain final product; 所述步骤⑴为将提取滤液浓缩至1:(1~2)ml/g,搅拌下缓慢加入乙醇至醇浓度为50%(v/v),静置12~18小时;The step (1) is to concentrate the extraction filtrate to 1: (1-2) ml/g, slowly add ethanol under stirring until the alcohol concentration is 50% (v/v), and let stand for 12-18 hours; 所述的步骤⑶为将三七粉与崩解剂混匀,加到步骤⑵所得的浸膏中制软材,制粒,干燥;The step (3) is to mix the Panax notoginseng powder and the disintegrating agent, add it to the extract obtained in the step (2) to make a soft material, granulate, and dry; 所述的崩解剂为2:1的交联聚维酮与交联羧甲基纤维素钠的组合。The disintegrant is a 2:1 combination of crospovidone and croscarmellose sodium. 2.如权利要求1所述的中药片剂,其特征在于,所述崩解剂的用量为2~3%,硬脂酸镁用量为1%。2. Chinese medicine tablet as claimed in claim 1, is characterized in that, the consumption of described disintegrant is 2~3%, and the consumption of magnesium stearate is 1%. 3.如权利要求1所述的中药片剂,其特征在于,制备500片该中药片剂的原料为:3. Chinese medicine tablet as claimed in claim 1, is characterized in that, the raw material of preparing 500 this Chinese medicine tablet is: 黄芪431g,川芎287g,丹参215g,三七144g,泽泻144g,桂枝144g,郁金144g,山楂144g,槐花72g,木香72g,冰片5.7g;交联聚维酮5g,交联羧甲基纤维素钠2.5g,硬脂酸镁3.8g;Astragalus 431g, Chuanxiong 287g, Salvia 215g, Panax notoginseng 144g, Alisma 144g, Guizhi 144g, Curcuma 144g, Hawthorn 144g, Sophora japonica 72g, Woody 72g, Borneol 5.7g; Crospovidone 5g, Croscarboxyl Sodium methylcellulose 2.5g, magnesium stearate 3.8g; 制备方法:Preparation: (1)取三七、冰片之外的上述原料,加3倍量的温水及4%的复合酶,所述复合酶为3:1的纤维素酶与果胶酶,混匀,50℃保温酶解1小时;补加蒸馏水至8倍量,水蒸汽蒸馏法提取2次,收集挥发油,第一次1小时,第二次加6倍量水0.5小时,合并煎液,过滤,滤液减压浓缩至1:1.5ml/g后加乙醇至醇浓度50%,静置12小时,过滤,滤液回收乙醇,浓缩,得浸膏,浸膏密度在50℃时为1.13;(1) Take the above-mentioned raw materials except Panax notoginseng and borneol, add 3 times the amount of warm water and 4% compound enzyme, the compound enzyme is 3:1 cellulase and pectinase, mix well, and keep warm at 50°C Enzyme hydrolysis for 1 hour; add distilled water to 8 times the amount, extract 2 times with steam distillation, collect volatile oil, the first time for 1 hour, add 6 times the amount of water for 0.5 hours for the second time, combine the decoction, filter, and decompress the filtrate After concentrating to 1:1.5ml/g, add ethanol to the alcohol concentration of 50%, let it stand for 12 hours, filter, recover ethanol from the filtrate, concentrate to obtain extract, and the density of the extract is 1.13 at 50°C; ⑵将三七、冰片分别粉碎至100目,备用;⑵ Crush notoginseng and borneol to 100 mesh respectively, and set aside; ⑶将交联聚维酮、交联羧甲基纤维素钠与三七粉混匀,加到步骤⑵所得的浸膏中制软材,制粒,干燥;(3) mix crospovidone, croscarmellose sodium and notoginseng powder, add to the extract obtained in step (2) to make a soft material, granulate, and dry; ⑷向步骤⑶所得颗粒中喷洒挥发油,加入冰片粉及硬脂酸镁,混匀,压片、包薄膜衣,即得;上述方法制得的该中药片剂的单位重量为0.76g/片,即规格为0.76g/片。(4) spray volatile oil in step (3) gained granule, add borneol powder and magnesium stearate, mix, tabletting, film coating, to obtain final product; The unit weight of this Chinese medicine tablet that aforesaid method makes is 0.76g/ piece, That is, the specification is 0.76g/piece.
CN201510275397.XA 2015-05-27 2015-05-27 A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof Active CN104856968B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510275397.XA CN104856968B (en) 2015-05-27 2015-05-27 A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510275397.XA CN104856968B (en) 2015-05-27 2015-05-27 A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof

Publications (2)

Publication Number Publication Date
CN104856968A CN104856968A (en) 2015-08-26
CN104856968B true CN104856968B (en) 2018-02-09

Family

ID=53903443

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510275397.XA Active CN104856968B (en) 2015-05-27 2015-05-27 A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof

Country Status (1)

Country Link
CN (1) CN104856968B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105106153B (en) * 2015-09-16 2018-01-05 韩志强 A kind of papaya tablet
CN105106151B (en) * 2015-09-16 2018-03-23 韩志强 A kind of tablet for curing fracture and preparation method thereof
CN105168160B (en) * 2015-09-28 2018-10-19 韩志强 A kind of tablet of antelope's horn for common cold and preparation method thereof
CN105497794A (en) * 2015-12-30 2016-04-20 平光制药股份有限公司 Cholesterol-lowering and antithrombotic traditional Chinese medicine composition for warming channels and activating collaterals and preparation method of cholesterol-lowering and antithrombotic traditional Chinese medicine composition
CN105497175A (en) * 2015-12-31 2016-04-20 吉林紫鑫药业股份有限公司 Method for preparing medicine for relaxing muscles, stimulating blood circulation, removing stasis and relieving pain
CN105561184A (en) * 2015-12-31 2016-05-11 吉林紫鑫药业股份有限公司 Medicinal composition for activating blood circulation, dissipating blood stasis, warming meridians and relaxing veins, and preparation method thereof
CN107164164A (en) * 2017-07-16 2017-09-15 钱如贵 A kind of preparation method of herb fermenting wine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1579520A (en) * 2004-05-19 2005-02-16 吉林省东北亚药业股份有限公司 Preparation for eliminating thrombus and promoting lactation, and its preparation method
CN1720988A (en) * 2005-07-29 2006-01-18 北京蓝贝望医药科技开发有限公司 Thrombus eliminating, channel activating soft capsule and its preparation method
CN1868533A (en) * 2005-12-31 2006-11-29 浙江天一堂集团有限公司 Traditional Chinese medicine soft capsule for eliminating thrombus and removing obstruction in channels, its prepn. method
CN103495117A (en) * 2013-10-09 2014-01-08 南京正亮医药科技有限公司 Preparation method and application of thrombus removing and collaterals dredging tablets

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1579520A (en) * 2004-05-19 2005-02-16 吉林省东北亚药业股份有限公司 Preparation for eliminating thrombus and promoting lactation, and its preparation method
CN1720988A (en) * 2005-07-29 2006-01-18 北京蓝贝望医药科技开发有限公司 Thrombus eliminating, channel activating soft capsule and its preparation method
CN1868533A (en) * 2005-12-31 2006-11-29 浙江天一堂集团有限公司 Traditional Chinese medicine soft capsule for eliminating thrombus and removing obstruction in channels, its prepn. method
CN103495117A (en) * 2013-10-09 2014-01-08 南京正亮医药科技有限公司 Preparation method and application of thrombus removing and collaterals dredging tablets

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
植物挥发油的提取技术研究进展;陈丛瑾等;《食品研究与开发》;20111130;第32卷(第11期);第151-156页 *

Also Published As

Publication number Publication date
CN104856968A (en) 2015-08-26

Similar Documents

Publication Publication Date Title
CN104856968B (en) A kind of Chinese medicinal tablet with eliminating thrombus and removing obstruction in channels effect and preparation method thereof
CN103877244B (en) A kind of pharmaceutical composition and preparation method thereof for treating headache
CN103055016A (en) Freeze-dried fresh rehmannia for treating acne
CN101904948A (en) Traditional Chinese medicine preparation of Xinzhongsheng pills and preparation method thereof
CN101757322B (en) A kind of herbal medicine compound preparation for treating gouty arthritis and its preparation and application
CN107496521A (en) Nourishing lung and activating blood capsule is preparing the purposes in treating chronic bronchitis medicine
CN106421673A (en) Traditional Chinese medicine composition for treating HPV (human papillomavirus) infection and preparation method thereof
CN103211948B (en) A kind of compound preparation for the treatment of primary osteoporosis and preparation method thereof
CN100427136C (en) A kind of pharmaceutical composition for treating fatty liver and its preparation method and application
CN102764294B (en) Cough relieving and sputum eliminating combination and preparation method thereof
CN113209166A (en) Anti-aging traditional Chinese medicine composition containing nicotinamide mononucleotide and preparation method thereof
CN102362842B (en) Preparation and application of traditional Chinese medicine compound extract with whitening and freckle removing effects
CN109224038B (en) Traditional Chinese medicine composition containing channel-inducing medicine evodia rutaecarpa for treating blood stasis collateral blocking type hepatic fibrosis and preparation method and application thereof
CN104257816B (en) A kind of composition for treating berloque dermatitis and preparation method thereof
CN102362901A (en) A kind of traditional Chinese medicine composition for treating chronic colitis and preparation method thereof
CN102670711B (en) White flower salviae miltiorrhizae extract for curing angiitis, preparation method and application
CN100455300C (en) Wild kiwifruit compound swallow tablet and preparation method thereof
CN108743893A (en) The preparation method and applications of clearing lung-heat soup side's Chinese medical extract
CN113712999A (en) Application of Zhuang medicine xue Dang dry paste powder in preparation of anti-inflammatory analgesic medicine
CN107184657A (en) It is a kind of to treat compound Chinese medicinal preparation of primary osteoporosis and preparation method thereof
CN112587572B (en) Application of Zhuang medicine Wuye alcohol extract in preparation of anti-gouty arthritis medicine
CN105168160B (en) A kind of tablet of antelope's horn for common cold and preparation method thereof
CN114028531B (en) A kind of medicine for treating breast cancer and its preparation method and application
CN103520315A (en) Medicinal composition for treating gynecological vaginitis and preparation method of medicinal composition
CN114601891B (en) Composition with anti-ulcerative colitis effect and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20191209

Address after: 064400 No. 2966, modern equipment manufacturing industry cluster, Qian'an City, Tangshan City, Hebei Province

Patentee after: Hebei Baishan Pharmaceutical Co.,Ltd.

Address before: 063000 Hebei Province, Tangshan City Road North North West Road No. 18

Patentee before: Han Zhiqiang

TR01 Transfer of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Traditional Chinese medicine tablet with effects of removing thrombus and dredging collaterals and preparation method thereof

Effective date of registration: 20200312

Granted publication date: 20180209

Pledgee: Bank of Cangzhou Limited by Share Ltd. Tangshan branch

Pledgor: Hebei Baishan Pharmaceutical Co.,Ltd.

Registration number: Y2020980000651

PE01 Entry into force of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20210219

Granted publication date: 20180209

Pledgee: Bank of Cangzhou Limited by Share Ltd. Tangshan branch

Pledgor: Hebei Baishan Pharmaceutical Co.,Ltd.

Registration number: Y2020980000651

PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: The invention relates to a traditional Chinese medicine tablet with the function of eliminating thrombus and dredging collaterals and a preparation method thereof

Effective date of registration: 20220107

Granted publication date: 20180209

Pledgee: Bank of Cangzhou Limited by Share Ltd. Tangshan branch

Pledgor: Hebei Baishan Pharmaceutical Co.,Ltd.

Registration number: Y2022980000150

PE01 Entry into force of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20230717

Granted publication date: 20180209

Pledgee: Bank of Cangzhou Limited by Share Ltd. Tangshan branch

Pledgor: Hebei Baishan Pharmaceutical Co.,Ltd.

Registration number: Y2022980000150

PC01 Cancellation of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A traditional Chinese medicine tablet with thrombolytic and unblocking effects and its preparation method

Effective date of registration: 20231222

Granted publication date: 20180209

Pledgee: Bank of Cangzhou Limited by Share Ltd. Tangshan branch

Pledgor: Hebei Baishan Pharmaceutical Co.,Ltd.

Registration number: Y2023110000547

PE01 Entry into force of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Granted publication date: 20180209

Pledgee: Bank of Cangzhou Limited by Share Ltd. Tangshan branch

Pledgor: Hebei Baishan Pharmaceutical Co.,Ltd.

Registration number: Y2023110000547

PC01 Cancellation of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A traditional Chinese medicine tablet with the function of reducing blood stasis and promoting blood circulation, and its preparation method

Granted publication date: 20180209

Pledgee: Bank of Cangzhou Limited by Share Ltd. Tangshan branch

Pledgor: Hebei Baishan Pharmaceutical Co.,Ltd.

Registration number: Y2024980058637

PE01 Entry into force of the registration of the contract for pledge of patent right